Who makes Apraclonidine 0.5%?

Apraclonidine 0.5% is developed by Walter Reed Army Medical Center.

What development phase is Apraclonidine 0.5% in?

Apraclonidine 0.5% is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Apraclonidine 0.5%

Walter Reed Army Medical Center · Phase 1 active Small molecule

At a glance

Generic name	Apraclonidine 0.5%
Sponsor	Walter Reed Army Medical Center
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis (PHASE2)
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Apraclonidine 0.5% CI brief — competitive landscape report
Apraclonidine 0.5% updates RSS · CI watch RSS
Walter Reed Army Medical Center portfolio CI